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Abstract
Background: This study set out to evaluate the effect of dose rate on normal tissues (the lung, in particular) and
the variation in the treatment efficiency as determined by the monitor unit (MU) and energy applied in Linac-based
volumetric arc therapy (VMAT) total marrow irradiation (TMI).
Methods: Linac-based VMAT plans were generated for the TMI for six patients. The planning target volume (PTV)
was divided into six sub-volumes, each of which had their own isocenter. To examine the effect of the dose rate
and energy, a range of MU rates (40, 60, 80, 100, 300, and 600 MU/min) were selected for 6, 10, and 15 MV. All the
plans were verified by portal dosimetry.
Results: The dosimetric parameters for the target and normal tissue were consistent in terms of the energy and
MU rate. The beam-on time was changed from 59.6 to 6 min for 40 and 600 MU/min. When 40 MU/min was set for
the lung, the dose rate delivered to the lung was less than 6 cGy/min (that is, 90%), while the beam-on time was
approximately 10 min. The percentage volume of the lung receiving 20 cGy/min was 1.47, 3.94, and 6.22% at 6, 10,
and 15 MV, respectively. However, for 600 MU/min, the total lung volume received over 6 cGy/min regardless of the
energy, and over 20 cGy/min for 10 and 15 MV (i.e., 54.4% for 6 MV).
Conclusions: In TMI treatment, reducing the dose rate administered to the lung can decrease the incidence of
pulmonary toxicity. To reduce the probability of normal tissue complications, the selection of the lowest MU rate is
recommended for fields including the lung. To minimize the total treatment time, the maximum MU rate can be
applied to other fields.
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Background
Total body irradiation (TBI) has long played an important
role as a conditioning regimen prior to bone marrow or
hematopoietic stem cell transplantation for patients with
hematologic malignancies (i.e., leukemia, lymphoma, or
multiple myeloma) [1]. The primary reason for the use of
TBI is the elimination of residual cancer cells and preventing
the immunologic rejection of the transplanted donor stem
cells [2]. The TBI treatments are generally performed at an
extended source-to-surface distance (SSD) with large open
fields to deliver a homogeneous dose to the entire body [3,
4]. In addition, TBI treatments have been performed using
techniques such as moving-beam TBI with a sweeping
beam, a patient translation technique, multiple-beam TBI, a
shrinking-field technique, and the local application of small
beams [5–7].
However, for patients with advanced acute leukemia, in-
creasing the total TBI dose may improve malignant clone
killing, but it is also associated with a potential lethal toxicity
to the surrounding normal healthy tissues/organs [8, 9]. The
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side effects of TBI can be extensive and include acute symp-
toms such as nausea and a loss of appetite, as well as infertil-
ity and secondary malignancies [10]. Pulmonary toxicity is
one of the most serious, and potentially life-threatening,
complications that may occur following TBI [11]. Therefore,
new techniques have concentrated on providing a safer dose
escalation [12, 13].
To deliver a therapeutic dose to a target, while not irradi-
ating normal tissue, total marrow irradiation (TMI) has been
introduced in combination with helical tomotherapy (HT)
or volumetric arc therapy (VMAT) using conventional lin-
ear accelerators [12, 14, 15]. TMI, when delivered with an
intensity-modulation (IM) technique, may reduce the dose
delivered to the organs at risk (OARs), relative to TBI. These
techniques have the potential to provide a safer dose escal-
ation for a target [16]. Several studies have shown the poten-
tial clinical benefits of IM-TMI [12–15, 17, 18].
For conventional TBI treatments, the dose rate is a signifi-
cant parameter. To minimize the dose rate, the patient is
generally located at an extended SSD of more than 400 cm
[3]. Many studies have reported that, when TBI is performed
with a low dose rate, the healthy tissue exhibits less damage
[8, 9, 11, 19, 20]. Especially, low dose rates (less than 6 cGy/
min) can decrease the risk of pulmonary toxicity [11, 19,
21]. However, TMI treatments with HT or VMAT have con-
ventionally been performed with relatively high dose rates
due to limitations on the dose rate selection and the treat-
ment location (i.e., at the isocenter). For example, the lowest
dose rate is 100 monitor units (MU)/min and 800 MU/min
for the Varian C-series Clinac® (Varian Medical Systems,
Palo Alto, CA) and HT, respectively. New delivery platforms
that can deliver low dose rates have been released by Varian.
Their VitalBeam™ (Varian Medical Systems, Palo Alto, CA)
and Truebeam™ systems (Varian Medical Systems, Palo Alto,
CA) offer dose rates of as low as 5 MU/min and 20 MU/
min for 6–10 MV and 15–20 MV, respectively. In VMAT
delivery mode, the dose rate can be varied during the treat-
ment. However, the maximum dose rate can be limited by
setting the dose rate in the planning process. If, in the plan
optimization, the dose rate is set to less than 100 MU/min,
which is supported by the C-series, a safe dose rate can be
delivered to the OARs, especially the lungs.
In this paper, we describe the plan quality of TMI
treatments with a range of MU rates and energies, per-
formed using a Vitalbeam system. The appropriate MU
rate setting was determined by evaluating the dose dis-
tribution, the dose rate to each OAR, and the duration
of the TMI treatment.
Materials and methods
Patient selection and simulation
Six patients being treated by TMI were enrolled in the
present study. Their participation in the study was ap-
proved by the institutional review board (IRB No.
H-1706-007-855). The height and weight of each patient
are listed in Table 1. All the patients were scanned using
the Brilliance CT Big Bore scanner (Philips, Amsterdam,
Netherlands) with a 3.0-mm slice thickness.
Treatment plan
A radiation oncologist defined the clinical target volume
(CTV) including all the bone marrow in the body from
the head to the mid-thighs, but excluding the forearms
and hands. The CTVs were segmented for the bone,
brain, liver, spleen, and testis. Regarding the lower ex-
tremities, one third of the upper femur (active marrow
region) was included for CTV definition.
To define the planning target volume (PTV), each
CTV was extended by adding a different margin in con-
sideration of the internal motion of each organ. The
brain, bone and testis PTV was defined by adding 3, 5,
and 7 mm to their CTVs, respectively. For the liver and
spleen PTV, a 5-mm margin was set in all except the
superior-inferior (SI) directions. For the SI direction, a
15-mm margin was applied.
The total PTV was defined as the sum of each PTV.
The total PTV was divided into sub PTVs for each isocen-
ter. A total of six isocenters were defined considering the
shape and length of the PTV. The sub PTVs were named
as follows: PTV_Brain, PTV_Chest1, PTV_Chest2,
PTV_Abdomen, PTV_Pelvic, and PTV_Femur. The lungs,
kidneys, eyes, oral cavities, bowels, and heart were desig-
nated as being OARs. The prescription dose was 10 Gy,
administered in five fractions [12]. The dose constraints of
the mean doses administered to the lungs, kidneys, blad-
der, and bowels were set to 6, 7, 8.5, and 7 Gy, respectively.
All the plans were normalized to cover 90% of the PTV
volume with 100% of the prescription dose. The patient
was treated once a day with a 2-Gy dose, administered by
the Vitalbeam system.
A VMAT-TMI treatment plan was generated using an
Eclipse™ system (Ver. 13.7, Varian Medical Systems, Palo
Alto, CA) with PRO 13.7 (progressive resolution
optimization, Ver. 13.7, VarianTM Medical Systems, Palo
Alto, CA) as the optimizer algorithm. The dose calculation
was performed using Acuros® XB 13.7 with a 2.5-mm grid.
A total of six arc fields corresponding to each isocen-
ter were created with inter-gantry angles of 179° and
Table 1 Patient information (height, weight, and gender)
Patient Height (cm) Weight (kg) Gender
1 185.6 72.2 M
2 161.5 51.3 F
3 170 73.1 M
4 163.2 62.5 F
5 163.6 64.8 M
6 164.8 55.9 M
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181°. Each field was fully opened to cover the entire
length of each sub PTV with a collimator rotation of 90°
or 180°. For TMI using a multi-isocenter, the verification
of the dose accumulation in a junction area should be
considered. Previous studies investigated the robustness
of the junctions [15, 17, 18]. Those studied have sug-
gested at least 2 cm overlapped region between the pre-
vious and following arc on each side to eliminate any
hot and cold spots. In the present study, the overlapping
regions between neighboring fields were set with at least
2 cm on each side to avoid there being hot or cold re-
gions around the field junctions following literature [15,
17, 18]. Figure 1 shows the arrangement of the field and
isocenter corresponding to each PTV.
First, a VMAT-TMI plan was generated by changing
the energy (6, 10, and 15 MV) with a dose rate of
600 MU/min, while maintaining the collimator angles,
field sizes, and number and location of the isocenters
for the total field. Next, new plans were created in
accordance with the changing MU rate (40, 60, 80,
100 and 300 MU/min) for each energy. For new cre-
ated plans, the each VMAT optimization was per-
formed with same optimization parameters.
One MU was calibrated while 1 cGy was delivered
to the maximum depth (e.g., 1.5, 2.5, and 2.9 cm
depth for 6, 10, and 15 MV) in a water phantom with
a 100-cm source to surface distance and a 10 × 10
cm2 field size.
Plan analysis
The beam-on time was calculated to evaluate the dose
rate for each field. To evaluate the non-linear correlation
between the dose rate and beam-on time, the non-linear
correlation factor was defined as the ratio of MUs to
beam-on times. The dosimetric quality was evaluated
with respect to the target coverage and OAR dose. For
the PTV, the dose parameters were analyzed using the
near-minimum (D98%), near-maximum, (D2%), and mean
absorbed doses, the latter being designated D50%. For the
OAR dose, the mean dose and V5Gy (cc) were evaluated.
The average dose rate delivered to the lungs was cal-
culated by dividing the mean dose by the beam-on time.
According to the guidelines published by the ACR and
the ASTRO, a dose rate to the lungs of less than 20 cGy/
min has been suggested to decrease the incidence of pul-
monary toxicity. Therefore, the average volume irradi-
ated at a dose rate of more than 20 cGy/min was
evaluated for the lungs. The PTV_Chest1 and
PTV_Chest2 isocenters were set to irradiate the chest
region including the lungs and ribs. The sum of the
beam-on time for PTV_Chest1 and PTV_Chest2 was
Fig. 1 Field arrangement for VMAT. Pictorial representation of total marrow irradiation (TMI) plan by volumetric arc therapy (VMAT) consisting of
six isocenters with a single arc. Field arrangement projected at isocenter in coronal plan (a) and sagittal plane (b)
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used as the beam-on time for calculating the average
dose rate for the entire lung.
Plan verification
The plans were verified using a Portal dosimetry system
with an electronic portal imaging device. The verifica-
tion plans were created using a portal dose image pre-
diction (PDIP, Ver 13.7, Varian Medical Systems, Inc.,
Palo Alto, CA) algorithm. For gamma index evaluation,
the criteria was set to a 2% dose difference and a 2-mm
distance to agreement. The threshold dose was set to
10%.
Results
The beam-on times and MU for each field, energy, and
dose rate are listed in Table 2. Figure 2 shows the
non-linear correlation factor between the MUs and
beam-on times. The beam-on time decreases as the en-
ergy increases. The beam-on time for field 1
(PTV_Brain) was the shortest. The non-linear correl-
ation factor increases dramatically with the MU rate.
Dose-volumetric parameters for each MU rate of TMI
by VMAT using 6, 10 and 15 MV was provided in sup-
plementary material (Additional file 1: Table S1).
The TMI isodose distributions in colorwash are illus-
trated in Fig. 3. The average values of the dose-volumetric
parameters of PTV and normal tissue for the energy and
dose rate of each patient are provided as supplementary
material. The different dose-volumetric parameters for the
energy and dose rates are not shown.
Figure 4 shows the dose-rate volumetric histogram for
the lung volume of a representative case (Patient 1).
When the 40-MU rate was used, the average volume of
the lung receiving a dose of less than 6 cGy/min was
92.45 ± 8.88%, 93.47 ± 6.53% and 94.04 ± 6.11% at 6, 10,
and 15 MV, respectively. The average lung volumes irra-
diated at a dose rate of more than 20 cGy/min are listed
in Table 3.
For all the plans, the gamma passing rate was more
than 90%. For those plans with 300 and 600 MU/min at
every energy, the gamma passing rate was 99%. For
those plans with 40, 60, and 80 MU/min at every energy,
the range of the gamma passing rate was 90–94%.
Discussion
In the present study, we evaluated the dose rate and
dosimetric parameter based on the MU rate of the ma-
chine and the energy.
TMI treatments using the VMAT technique are clinic-
ally favorable in that they can overcome the limitations
of TBI since TMI can reduce the dose administered to
an OAR. Additionally, the accuracy of the TMI treat-
ment can be improved using an image guidance system.
However, there remain issues with the dose rate when
using TMI delivery with a C-series or HT device. How-
ever, this problem has been solved by the release of new
machines with a low MU rate.
The radiation toxicity of a normal organ, especially the
incidence of pulmonary toxicity, is a major factor deter-
mining the prescription dose for patients with hemato-
lymphoid malignancies [8, 11, 19, 21]. Pulmonary
toxicity can significantly affect the overall survival rate.
The dose rate administered to the lung is a key factor, as
well as the total dose. The published guidelines recom-
mend that TBI treatments not exceed a dose rate of 20
cGy/min [21]. TBI with a dose rate of less than 6 cGy/
min can reduce pulmonary toxicity [11, 19]. When 40
MU/min was set for the PTV_Chest1 and 2 fields, the
lung volume receiving less than 6 cGy/min was 90%
while the beam-on time of two field (PTV_Chest1 and
2) was 10 min, approximately. However, if MU/min was
set for all the fields, the total treatment time would be
60min. This long treatment time can result in increasing
the intra-fraction error (e.g., breathing movement or pa-
tient motion. Moreover, the patient can feel discomfort
due to lying down on the couch with an immobilization
device. To avoid such an adverse effect, we can select
the proper MU rate for a specific field which includes an
OAR such as the lung. If the maximum MU rate (i.e.,
600 MU/min) is applied to the PTV_Brain, Pelvic and
Femur fields with 40MU/min for PTV_Chest1 and 2
only, the beam-on time was approximately 24 min. Even
if the imaging acquisition time is included, the total
treatment can be finished within 1 h. For imaging guide,
cone beam computed tomography (CBCT) was taken
for each single isocenter. The reference CT image set
and digitally reconstructed radiograph was compare to
CBCT and pair of orthogonal kV radiographs.
However, in terms of dose voxel, each voxel in OAR
has a different dose rate. Each beam of field beam is sub-
divided into hundreds of beamlets. The voxel was par-
tially irradiated by beamlet which have an individual
intensity level [22]. In this study, the dose rate was cal-
culated under the assumption that the dose to OAR is
sum total of dose during beam on time.
The total dose administered to the lung did not exhibit
any dependency on the energy. However, the beam-on
time decreased slightly as the energy increased, except
when the dose rate was 600 MU/min. A higher energy
can result in the delivery of a similar dose in less time
with a limited MU rate. However, when the maximum
MU rate (600 MU/min) is allowed, the machine can de-
liver a sufficiently high dose rate at the maximum gantry
speed. The beam-on time with an MU rate of 600 MU/
min was constant since the beam-on time is predomin-
antly determined by the maximum gantry speed.
The PTV should include the ribs since the bone mar-
row is primarily located in the ribs. The lungs, which are
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Fig. 3 Isodose distributions. Isodose distributions in colorwash of TMI by VMAT for 6 (a), 10 (b), and 15 MV (c). Dose range: 20% (blue) to 120% (red)
Fig. 2 Non-linear correlation factor. The factors were defined as a ratio of total MU to beam-on time. 6 MV (black solid line), 10 MV (red solid line)
and 15 MV (blue solid line)
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the most important OARs, are enclosed by the ribs. In
planning the processing, we tried to reduce the dose ad-
ministered to the lungs as far as possible. However, it
was a difficult to reduce this dose due to the PTV cover-
age including the ribs. The DVH of the lung had a steep
dose gradient with a range of 3–10 Gy.
The beam-on time and dose slightly decreased with an
increase in the energy. With conventional TBI treat-
ment, high-energy beams (10–18 MV) have historically
been used, particularly for patients for which the thick-
ness is greater than 35 cm, and therefore considered to
be homogenous. However, when high-energy photon
beams of more than 10 MV were used, the photoneu-
trons can lead to an increase in the undesired dose to
the patient [23]. TMI techniques using 10 and 15 MV
offer no advantages in consideration of the higher inte-
gral dose, larger penumbra and similar beam-on time
and dose rate.
The variation in the MU rate was extremely limited
relative to the general capacity of the machine. The
optimization was processed with the extra constraints
for a treatment plan with a lower dose rate. Therefore,
plan verification was performed to check the delivery ac-
curacy. The gamma passing rates of the plan with the
lower MU rate were lower than those with the higher
dose rate. The response of the Si detector used to per-
form portal dosimetry can be affected by the dose rate.
The relatively low gamma passing rate was caused by
this effect [24]. However, in every case, the gamma pass-
ing rate was more than 90%. All the plans could be de-
livered clinically.
In this study, the part of the lower extremity (i.e. lower
legs from mid-femurs) was not included in VMAT
optimization. The current treatment table on the LINAC
has a maximum travel length of approximately 150 cm
in longitudinal direction [25]. Therefore, two different
plans are required for TMI which includes lower leg. In
literature, reverse patient position approach has been in-
troduced [18]. However, the field junction problem
should be considered carefully for the approach [17].




40 60 80 100 300 600
6 1.47 ± 1.56 24.42 ± 14.08 49.19 ± 14.28 69.59 ± 13.56 53.96 ± 28.69 54.40 ± 28.88
10 3.91 ± 3.90 30.81 ± 14.01 54.18 ± 12.02 71.24 ± 12.15 100.00 ± 0.00 100.00 ± 0.00
15 6.22 ± 6.14 35.10 ± 13.30 57.63 ± 11.59 74.58 ± 11.95 100.00 ± 0.00 100.00 ± 0.00
Fig. 4 Dose-rate versus lung volume histogram. Dose-rate versus lung volume histogram of representative case for 6 MV (solid line), 10 MV (dotted
line), and 15 MV (dashed line) according to the monitor unit (MU) rate. Black: 40 MU/min, red: 60 MU/min, green: 80 MU/min, blue: 100 MU/min, cyan:
300 MU/min and magenta: 600 MU/min
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VMAT plan could be generated for this part in feet-first
position, keeping an overlapping region with the upper
sector to prevent the risk of cold or hot spots [25].
Conclusion
We evaluated the beam-on time and dose volume param-
eter for given energies and MU rates for VMAT TMI. The
dose volume parameter was found to be not dependent
on the energy and MU rate. However, the received PTV
dose rate for normal tissue was found to differ signifi-
cantly with the MU rate. In the case of TMI, the dose rate
delivered to the lung is critical. To reduce the probability
of normal tissue complications, the selection of the lowest
MU rate was recommended for fields included the lung.
Considering the total treatment time, maximum dose rate
can be selected for other fields.
Additional file
Additional file 1: Table S1. Dose-volumetric parameters for each MU
rate of TMI by VMAT using 6, 10 and 15 MV. (XLSX 17 kb)
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